Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Jun 14 2024

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received tentative approval from the USFDA for Azilsartan Medoxomil and Chlorthalidone Tablets. The tablets are indicated for the treatment of high blood pressure and will be manufactured in Ahmedabad. The press release also notes that the drug had significant annual sales in the United States.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated Jun 14, 2024, titled "Zydus receives tentative approval from USFDA for Azilsartan Medoxomil and Chlorthalidone Tablets".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases